Reviewing Horizon Therapeutics


Horizon Therapeutics and Peregrine Pharmaceuticals are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Peregrine Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 162.47%.



from Biotech News